Full Text
EE504 Cost-Effectiveness Analysis of Tremelimumab As First-Line Therapy for Metastatic Non-Small Cell Lung Cancer in Japan

Abstract

Authors

R Sakai K Moriwaki K Morimoto K Shimozuma

Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×